FDA Approves Pfizer's Ruxience Rituximab Biosimilar

 
• By Dave Wallace

Pfizer has received approval from the US Food and Drug Administration for the country’s second biosimilar rituximab, under the Ruxience label. However, the company has not yet revealed launch plans for the rival to Roche’s Rituxan brand.

FDA Approved
FDA Approval Has Been Received, But Launch Plans Are Still Under Lock And Key • Source: Shutterstock

More from Biosimilars

More from Products